133 related articles for article (PubMed ID: 17176979)
21. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
22. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
[TBL] [Abstract][Full Text] [Related]
23. PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas.
Sattar T; Griffeth LK; Latifi HR; Glass J; Munker R; Lilien DL
J La State Med Soc; 2006; 158(4):193-201. PubMed ID: 17022364
[TBL] [Abstract][Full Text] [Related]
24. A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography.
Thie JA; Hubner KF; Isidoro FP; Smith GT
Mol Imaging Biol; 2007; 9(2):91-8. PubMed ID: 17205367
[TBL] [Abstract][Full Text] [Related]
25. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
26. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
Bodet-Milin C; Kraeber-Bodéré F; Moreau P; Campion L; Dupas B; Le Gouill S
Haematologica; 2008 Mar; 93(3):471-2. PubMed ID: 18310543
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
30. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
Noy A; Schöder H; Gönen M; Weissler M; Ertelt K; Cohler C; Portlock C; Hamlin P; Yeung HW
Ann Oncol; 2009 Mar; 20(3):508-12. PubMed ID: 19139176
[TBL] [Abstract][Full Text] [Related]
31. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
[TBL] [Abstract][Full Text] [Related]
32. Addressing glucose sensitivity measured by F-18 FDG PET in lung cancers for radiation treatment planning and monitoring.
Wong CY; Thie J; Gaskill M; Kestin L; Yan D; Cheng V; Nagle C
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):132-7. PubMed ID: 16472939
[TBL] [Abstract][Full Text] [Related]
33. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
34. Kikuchi-Fujimoto disease: PET/CT assessment of a rare cause of cervical lymphadenopathy.
Tsujikawa T; Tsuchida T; Imamura Y; Kobayashi M; Asahi S; Shimizu K; Tsuji K; Okazawa H; Kimura H
Clin Nucl Med; 2011 Aug; 36(8):661-4. PubMed ID: 21716016
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
36. Exceptionally low metabolic activity in aggressive peripheral T-cell lymphoma.
Tang B; Douglas-Nikitin V; Balon H; Wong CO; Khong PL; Wong CY
Nucl Med Commun; 2009 Nov; 30(11):838-40. PubMed ID: 19734816
[TBL] [Abstract][Full Text] [Related]
37. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
[TBL] [Abstract][Full Text] [Related]
38. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
39. Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status.
Kumar R; Chauhan A; Zhuang H; Chandra P; Schnall M; Alavi A
Mol Imaging Biol; 2006; 8(6):355-62. PubMed ID: 17053861
[TBL] [Abstract][Full Text] [Related]
40. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
